About Galactose-3-O-sulfotransferase 4
Galactose-3-O-sulfotransferase 4 (GAL3ST4) is a protein
from Homo sapiens identified by UniProt accession
Q96RP7, 486 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | Galactose-3-O-sulfotransferase 4 |
| UniProt accession | Q96RP7 |
| Gene | GAL3ST4 |
| Organism | Homo sapiens |
| Length | 486 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (26)
Diseases linked to this target (Open Targets).
- age at menarche · score 0.12
- forced expiratory volume · score 0.08
- diet measurement · score 0.07
- mean corpuscular volume · score 0.05
- leprosy · score 0.05
- cortical thickness · score 0.04
- FEV/FVC ratio · score 0.03
- neuroimaging measurement · score 0.03
- brain measurement · score 0.03
- diastolic blood pressure · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96RP7-F1 | alphafold | PREDICTED | 79.32 | — |
Amino-acid sequence (486 residues)
MGPLSPARTL RLWGPRSLGV ALGVFMTIGF ALQLLGGPFQ RRLPGLQLRQ PSAPSLRPAL PSCPPRQRLV FLKTHKSGSS SVLSLLHRYG DQHGLRFALP ARYQFGYPKL FQASRVKGYR PQGGGTQLPF HILCHHMRFN LKEVLQVMPS DSFFFSIVRD PAALARSAFS YYKSTSSAFR KSPSLAAFLA NPRGFYRPGA RGDHYARNLL WFDFGLPFPP EKRAKRGNIH PPRDPNPPQL QVLPSGAGPR AQTLNPNALI HPVSTVTDHR SQISSPASFD LGSSSFIQWG LAWLDSVFDL VMVAEYFDES LVLLADALCW GLDDVVGFMH NAQAGHKQGL STVSNSGLTA EDRQLTARAR AWNNLDWALY VHFNRSLWAR IEKYGQGRLQ TAVAELRARR EALAKHCLVG GEASDPKYIT DRRFRPFQFG SAKVLGYILR SGLSPQDQEE CERLATPELQ YKDKLDAKQF PPTVSLPLKT SRPLSP
Explore Galactose-3-O-sulfotransferase 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets